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INTRODUCTION
High-mobility group box 1 (HMGB1)
regulates cell functions in a diverse and
compartment-specific manner (1,2). These
include the regulation of gene transcrip-
tion and DNA repair responses in the nu-
cleus, nucleic acid sensing and cell metab-
olism in the cytoplasm and mitochondria
and complex messenger functions in the
extracellular space (1,2). HMGB1 released
from cells either passively (that is, during
necrosis) or actively (that is, via secretion)
triggers signaling through numerous re-
ceptors to regulate cytokine production,
cell chemotaxis and tissue regeneration
(1,2). The pleotropic nature of HMGB1-
 receptor interactions involves at least two
mechanisms. First, HMGB1 interacts with
a wide range of other ligands, such as
CXCL12 (3) and IL-1 (4) to enhance the in-
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Extracellular high-mobility group box 1 (HMGB1) (disulfide form), via activation of toll-like receptor 4 (TLR4)-dependent signaling, is a
strong driver of pathologic inflammation in both acute and chronic conditions. Identification of selective inhibitors of HMGB1-TLR4 sig-
naling could offer novel therapies that selectively target proximal endogenous activators of inflammation. A cell-based screening strat-
egy led us to identify first generation HIV-protease inhibitors (PI) as potential inhibitors of HMGB1-TLR4 driven cytokine production. Here
we report that the first-generation HIV-PI saquinavir (SQV), as well as a newly identified mammalian protease inhibitor STO33438 (334), po-
tently block disulfide HMGB1-induced TLR4 activation, as assayed by the production of TNF-α by human monocyte-derived macro -
phages (THP-1). We further report on the identification of mammalian cathepsin V, a protease, as a novel target of these inhibitors. Cel-
lular as well as recombinant protein studies show that the mechanism of action involves a direct interaction between cathepsin V with
TLR4 and its adaptor protein MyD88. Treatment with SQV, 334 or the known cathepsin inhibitor SID26681509 (SID) significantly improved
survival in murine models of sepsis and reduced liver damage following warm liver ischemia/reperfusion (I/R) models, both character-
ized by strong HMGB1-TLR4 driven pathology. The current study demonstrates a novel role for cathepsin V in TLR4 signaling and implicates
cathepsin V as a novel target for first-generation HIV-PI compounds. The identification of cathepsin V as a target to block HMGB1-TLR4-
driven inflammation could allow for a rapid transition of the discovery from the bench to the bedside. Disulfide HMGB1 drives pathologic
inflammation in many models by activating signaling through TLR4. Cell-based screening identified the mammalian protease cathepsin
V as a novel therapeutic target to inhibit TLR4-mediated inflammation induced by extracellular HMGB1 (disulfide form). We identified two
protease inhibitors (PIs) that block cathepsin V and thereby inhibit disulfide HMGB1-induced TLR4 activation: saquinavir (SQV), a first-
 generation PI targeting viral HIV protease and STO33438 (334), targeting mammalian proteases. We discovered that cathepsin V binds
TLR4 under basal and HMGB1-stimulated conditions, but dissociates in the presence of SQV over time. Thus cathepsin V is a novel target
for first-generation HIV PIs and represents a potential therapeutic target of pathologic inflammation.
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teraction of the complex with the cognate
receptor of the ligand-binding partner (3).
Second, the redox status of the three cys-
teines (C23, C45 and C106) within
HMGB1 determines both the efficiency of
binding to other ligands as well as the
specificity of HMGB1 for certain receptors
(5). For example, when in the all-thiol
configuration, HMGB1 binds to CXCL12
(SDF1) to amplify the activation of
CXCR4 on immune and progenitor cells
promoting chemotaxis. In contrast, under
mild oxidizing conditions, C23 and C45
can form a disulfide bond and, if C106 re-
mains in the thiol configuration, HMGB1
binds avidly to MD2 to activate the
MD2/toll-like receptor 4 (TLR4) receptor
complex leading to inflammatory signal-
ing (6). This isoform is called the disulfide
form of HMGB1 (7).
Experimental studies suggest that ex-
cessive or sustained HMGB1-TLR4 acti-
vation can lead to immunopathology in
the acute setting. This has been observed
in ischemia/reperfusion (I/R) (8), hem-
orrhagic shock (9), trauma (10), NSAID
toxicity (11), acute lung injury (12) and
islet survival after transplantation (13);
and in the more chronic setting of in-
flammation associated with epileptic
seizures (14), pulmonary arterial hyper-
tension, (15) as well as responses to
chemotherapy (16). Thus, inhibitors that
limit HMGB1- mediated TLR4 activation
would be beneficial in a number of clini-
cally relevant settings. The discovery that
disulfide HMGB1 is the isoform that trig-
gers TLR4/MD2 signaling allowed us to
screen for agents that suppress disulfide
HMGB1-induced TNF-α production by
macrophages (17). A screen of 5,546
FDA-approved drugs yielded first gener-
ation HIV-protease inhibitors (PI) as ef-
fective inhibitors (18).
As shown in the current report, our
search for mammalian targets of first
generation HIV-PI involved in HMGB1-
induced TLR4 activation identified
cathepsin V (also called cathepsin L2) as
both susceptible to inhibition by HIV-PI
and required for TLR4 signaling. These
findings open the way for the therapeu-
tic repurposing of saquinavir and other
HIV-PI inhibitors for the experimental
treatment of inflammation.
MATERIALS AND METHODS
Reagents
OPTI-MEM (Invitrogen) was used as
treatment buffer. Recombinant rat
HMGB1, expressed in E. coli, was pro-
vided by KJ Tracey (24). LPS was an 
InvivoGen product. STO33438 (5-nitro-2-
[(5- [phenoxymethyl]-4-phenyl-1,2,4-
triazol-3-yl)sulfanyl]pyridine), (Timtec)
and SID26681509 (SID; Tocris) were dis-
solved to 10 mmol/L in 100% DMSO. All
the HIV protease inhibitors were pro-
vided by Y Al-Abed.
Animals
Male C57BL/J6 or BALB/c mice were
from The Jackson Laboratory. All animal
procedures were carried out in accor-
dance with the guidelines set by the Uni-
versity of Pittsburgh or Feinstein Insti-
tute’s Institutional Animal Care and Use
Committee (IACUC) and with IACUC
approval.
Antibodies
Anti-human cathepsin V (MAB10801,
R&D Systems), anti-HA (ab-hatag, In-
vivoGen), anti-human TLR4 (IMG-578A,
IMGENEX), anti-human MyD88 (4283,
Cell Signaling), anti-human IRAK4 (4363,
Cell Signaling ), anti-human IRAK1
(4504, Cell Signaling).
Cell Culture and Plasmids
Peritoneal macrophages were isolated
and cultured as described previously
(17). Human monocytic THP-1 cells were
differentiated for 12 h with 200 ng/mL
PMA. HEK293 (ATCC) and HEK293 sta-
bly transfected with CD14/MD2 and
TLR4-HA (InvivoGen) were grown at
37°C and 5% CO2, in DMEM (10% FBS, 
2 mmol/L L-GLN, 100 U/mL PS, 
1 mmol/L NaP, 100 μg/mL Normocin)
(InvivoGen).
Plasmids
pUNO-hTLR4-HA plasmid expressing
the human TLR4 gene fused at the 3′ end
to the influenza hemaglutinine (HA) and
pDUO-MD2/CD14 plasmid coexpress-
ing MD2 and CD14 genes (InvivoGen)
were transfected into HEK293 cells using
Genejammer transfection agent (Agilent)
and Blasticidin (InvivoGen).
Histology
Formalin-fixed, paraffin-embedded
livers were sectioned, hematoxylin-
eosin stained and assessed for tissue
damage.
Coimmunoprecipitation and
Immunoblot
Cells were lysed in 1% NP-40, 
50 mmol/L Tris-HCl (pH 7.4), 
150 mmol/L NaCl, 10% glycerol and 
protease inhibitors (Sigma-Aldrich,
Roche). After clearing by centrifugation,
total protein content was quantified
using a BCA kit and 1000 μg were im-
munoprecipitated (IP) overnight using 
anti-mouse/ rabbit beads (Rockland) and
corresponding antibodies. IP and input
fractions were subjected to SDS-PAGE
and Western blot analysis.
LDH Cytotoxicity
LDH cytotoxicity was performed ac-
cording to the manufacturer’s instruc-
tions (LDH kit, Takara Bio).
Cytokine and Chemokine Release
Cell supernatants were assayed by 
enzyme-linked immunosorbent assay
(ELISA) for TNF-α, IL-6 (R&D Systems)
according to the manufacturer’s instruc-
tions. IL-12p40, IP-10, MCP-1, MIP-1α
and KC were determined by Luminex
(Millipore).
Cecal Ligation and Puncture (CLP)
To establish live intraabdominal infec-
tion and sepsis, mice were subjected to
the CLP procedure (19). After intramus-
cular anesthesia (ketamine: 75 mg/kg,
Fort Dodge Lab and xlyazine: 20 mg/kg,
Boehringer Ingelheim), a 15-mm midline
incision was made to expose the cecum.
After ligation 5.0 mm from the tip, the
cecal stump was punctured once with a
22G needle and a small amount of stool
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extruded. The cecum was placed back
into its normal position and the wound
closed with two layers of running suture.
All animals received saline solution
(0.9% NaCl, 20 mL/kg of body weight.)
resuscitation and a single dose of antibi-
otic (NaCl 0.5 mg imipenem/mouse in
saline; Primaxin, Merck) 30 min after the
surgery. Saquinavir (SQV), 334 was given
intraperitoneal (IP) each day for 3 d
starting at 24 h after CLP surgery. Con-
trols mice received injection of vehicles.
Survival was monitored for 2 wks.
Warm Liver Ischemia/Reperfusion
A midline laparotomy was performed
in anesthetized mice (ketamine 100 mg/kg
and xylazine 10 mg/kg) and the hepatic
lobes freed by dividing the surrounding
ligaments. By using a microatraumatic
vascular clamp (Fine Science Tools), 70%
segmental ischemia was achieved,
whereas the blood supply to the remain-
ing liver lobes remained patent to avoid
intestinal venous congestion. The incision
was covered with a piece of saline-soaked
gauze and plastic film to reduce dehydra-
tion, and mice were placed on a heating
pad to maintain a rectal temperature of
37°C. The clamp was removed after
60 min to initiate hepatic reperfusion and
the abdominal incision was closed with
running 4-0 Vicryl-plus sutures (Ethicon).
Sham-treated mice underwent the same
manipulation, except that the vascular
clamp was not applied (20).
Surface-Plasmon Resonance Analysis
(BIAcore)
Analysis of binding of recombinant
human cathepsin V (1080-CY-010, R&D
Systems) to recombinant human TLR4
(1478-TR-050, R&D Systems) was con-
ducted using BIAcore 3000 instrument
(BIAcore Inc.). Binding reactions were
done in HBS-EP buffer (BIAcore Inc.). The
CM5 dextran chip (flow cell 2) was acti-
vated with an injection of 35 μL of 
0.1 mol/L N-ethyl-N′-[3-diethylamino-
propyl]-carbodiimide and 0.1 mol/L 
N-hydroxysuccinimide. TLR4 protein was
coated on the surface of a CM5 dextran
sensor chips by direct immobilization. An
aliquot of 100 μL of 10 μg/mL dilution of
human TLR4 protein in 10 mmol/L
NaOAc, pH 4.5 was injected into flow
cell-2 of CM5 chip to get the levels of 650
resonance units for the immobilization,
followed by 35 μL injection of 1 mol/L
ETA, pH 8.2 to block the remaining active
sites. The flow cell-1, without immobi-
lized TLR4-coated, was activated, blocked
and evaluated for nonspecific binding.
Binding analyses were performed at a
flow rate of 30 μL/min at 25°C. To evalu-
ate binding, the analytes (60 μL of cathep-
sin V, 0–10 μmol/L) were injected into
flow cell-1 and -2 and the association of
analyte and ligand was recorded respec-
tively by surface-plasmon resonance. The
signal from the blank channel (flow cell-1)
was subtracted from the channel contain-
ing purified TLR4 proteins (cell 2). Results
were analyzed using the software BIAeval
3.2 (BIAcore Inc.). For all samples, a blank
injection with buffer alone was subtracted
from the resulting reaction surface data.
Data were globally fitted to the Lagmuir
model for a 1:1 binding (21).
siRNA Transfection of THP-1 Cells
siCathepsin V (4392420) and siControl
(Ambion) were reconstituted to 
100 μmol/L. Cells were transfected
using Lipofectamine2000 (Invitrogen) ac-
cording to the manufacturer’s instruc-
tions (20 nmol/L siRNA) and differenti-
ated after 12 h with PMA (100 nmol/L
for 2 h), rinsed and incubated O/N be-
fore treatment.
Assessment of Cathepsin V Activity
Recombinant cathepsin V, reconsti-
tuted in 25 mmol/L MES, 5 mmol/L
DTT, pH 5.5 was kept on ice for 20 min.
The reconstituted enzyme was mixed
with vehicle (DMSO 0.1%) or increasing
concentrations of inhibitor (0.1; 0.3; 1; 3;
10; 30 μmol/L) followed by 20 min incu-
bation on ice. The fluorogenic peptide
substrate Z-LR-AMC was added and ac-
tivity assessed for 10 min using a spec-
trophotometer. Final amount of cathep-
sin V was 8 ng/well and 10 μmol/L for
substrate. The IC50 values were calcu-
lated using GraphPad Prism 6.
Statistical Analysis
Data are expressed as means ± SEM
from at least two or three independent
experiments. One-way analysis of vari-
ance (ANOVA) with Tukey post hoc test
was used for comparison among all dif-
ferent groups. Survival curves were ana-
lyzed by Fisher exact test in Figure 4. 
A P value of < 0.05 was considered statis-
tically significant: *P < 0.05; **P < 0.01; 
#P < 0.001, unless otherwise indicated.
All supplementary materials are available
online at www.molmed.org.
RESULTS
First-Generation HIV-Protease
Inhibitors Block HMGB1-Induced 
TNF-α Production
Our recent screening of 5,546 pharma-
cologically active compounds and clini-
cally used drugs identified several classes
of compounds, including HIV-protease
inhibitors as potent inhibitors of disulfide
HMGB1-induced TNF-α production in
RAW 246.7 macrophages (18). Therefore,
we tested the capacity of seven HIV-
 protease inhibitors currently in clinical
use, to inhibit TNF-α production in re-
sponse to disulfide HMGB1 in cultured
human monocyte-derived-macrophages.
These cells are human THP-1 cells stimu-
lated with PMA to allow for differentia-
tion into macrophages. SQV and
 nelfinavir (NFV), two first generation
HIV-protease inhibitors, were most effec-
tive in suppressing TNF-α production
(Figure 1A). A similar profile was ob-
served in parallel experiments using
freshly isolated mouse peritoneal
macrophages. These cells also responded
to SQV and nelfinavir as well as indi-
navir (Supplementary Figure S1A).
Because SQV exhibited the greatest po-
tency, we further characterized its in-
hibitory activity and mechanism of ac-
tion. SQV also suppressed, but to a
lesser extent, TNF-α production in re-
sponse to LPS, another TLR4 agonist in
human monocyte-derived macrophages
(Figure 1B) and did not induce toxicity
(Figure 1C). In parallel experiments
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using freshly isolated mouse peritoneal
macrophages, SQV not only inhibited the
HMGB1-stimulated production of TNF-α
but also IL-6, IL-12p40, IP10, MCP-1 and
MIP-1α, without inducing toxicity (Sup-
plementary Figures S1B–E).
Screening of Known Protease
Inhibitors Identifies STO33438
HIV-protease inhibitors were designed
to block the viral HIV protease. We hy-
pothesized that the observed effects of
HMGB1-induced inflammation relate to
their off-target action on a mammalian
protease involved in HMGB1-TLR4 sig-
naling. To aid in the identification of this
putative mammalian protease target we
screened the TimTec ACTITARG-P library
composed of known inhibitors of mam-
malian proteases. Of the 1,520 inhibitors
tested in Raw 264.7 cells, we identified
three hit compounds: ST033438 (334),
ST057867 (578) and ST056797 (567) that
were able to inhibit HMGB1-induced
TNF-α production by 45.1%, 41.3% and
36.2% respectively (Supplementary 
Table 1). We further confirmed that 334
blocked HMGB1-induced TNF-α pro-
duction in human monocyte-derived
macrophages and does not induce toxic-
ity (Figures 1D, E). We obtained parallel
results in freshly isolated mouse peri-
toneal macrophages (Supplementary Fig-
ures S1F, G). Like SQV, the inhibitory ac-
tivity of 334 was not limited to TNF-α but
included several other cytokines and
chemokines (Supplementary Figure 2F).
Identification of Cathepsin V as a
Target for SQV and 334
To identify the mammalian targets of
SQV and 334, the inhibitory activity of
these compounds was assessed against
58 known human proteases (Supplemen-
tary Table 2). Only human cathepsin V
was substantially inhibited by both com-
pounds tested (Supplementary Table 2).
Protease activity assays demonstrated
strong inhibition of recombinant human
cathepsin V by SQV and 334 (Figure 2A)
and IC50 values for SQV and 334 were
calculated and compared with a known
inhibitor of cathepsin, SID, as well as a
broad acting protease inhibitor E64 (Fig-
ure 2B). SID, originally synthesized to in-
hibit cathepsin L (22) (now a Tocris prod-
uct), also has been shown to inhibit
cathepsin V (23). In our experiments,
SQV, 334, SID and E-64 inhibited
cathepsin V activity with IC50 values of
3.30 μmol/L, 1.13 μmol/L, 0.50 μmol/L
and 0.12 μmol/L respectively as shown
in Figure 2B. To further explore the role
of cathepsin V in HMGB1- induced 
TNF-α production, we suppressed
cathepsin V expression in human 
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Figure 1. Protease inhibitor screen in human monocyte-derived macrophages identifies
Saquinavir (SQV) and ST033438 (334) as potent inhibitors of HMGB1-induced TNF-α produc-
tion. (A) The effect of various first generation HIV protease inhibitors on HMGB1- induced
TNF-α production as assessed by ELISA (VEH, vehicle; SQV, saquinavir; IDV, indinavir; RTV, 
ritonavir; DRV, darunavir; LPV, lopinavir; ATV, atazanavir; NFV, nelfinavir) after 1 h of drug pre-
treatment followed by 18 h HMGB1 stimulation (B) Effect of SQV on HMGB1- induced versus
LPS-induced TNF-α production in human monocyte-derived macrophages. (C,E) Cytotoxi-
city of SQV and 334 was determined by measuring LDH release into cell media after 18 h
of treatment. (D) Effect of STO33438 (334) on HMGB1-induced TNF-α in human monocyte-
 derived macrophages.
monocyte-derived macrophages using
siRNA prior to HMGB1 treatment. Inhi-
bition of cathepsin V protein expression
attenuated TNF-α production in response
to HMGB1 (Figures 2C, D; p < 0.001). As
a secondary method to confirm the role
of cathepsin V in TNF-α production,
human monocyte-derived macrophages
were also treated with the known
cathepsin inhibitor, SID. As expected,
SID blocked HMGB1- induced TNF-α
production dose dependently (Figure 2E)
without altering cell viability (Figure 2F).
We obtained parallel results in freshly
isolated mouse peritoneal macrophages
(Supplementary Figures S2A–C).
These combined findings identify
human cathepsin V as a target for the
protease inhibitor SQV and confirm a
role for cathepsin V in HMGB1-induced
macrophage activation through TLR4.
SQV Inhibits the Interaction between
Cathepsin V and the TLR4-MyD88
Receptor Complex
To determine if cathepsin V interacts
directly with TLR4, HA-tagged human
TLR4 was transfected into HEK 293 cells
and reciprocal immunoprecipitation ex-
periments were performed (Figures 3A, B).
Cathepsin V coimmunoprecipitated with
HA-TLR4 after HA pull-down and HA-
TLR4 coimmunoprecipitated with cathep-
sin V after cathepsin V pull-down (Fig-
ures 3A, B). A direct interaction of
cathepsin V with TLR4 was also estab-
lished using biacore analysis. Recombi-
nant cathepsin V was found to bind to
human TLR4 with a Kd of 1.5 μmol/L
(Figure 3C). This interaction was dose de-
pendently inhibited by SQV (0.625, 1.25,
2.5 and 5 μmol/L). Experiments using
human monocyte-derived macro phages
revealed basal interaction between
cathepsin V and TLR4 that increased due
to HMGB1 stimulation and was dis-
rupted by SQV (Figure 3D). Further ex-
ploration of the TLR4/Myd88/IRAK4
complex demonstrated additional inter-
actions of cathepsin V with IRAK4 as
well as TLR4 with Myd88 in response to
HMGB1 and was followed by its dissoci-
ation after SQV treatment (Figure 3D). A
quantitation of multiple immunoprecipi-
tation experiments shows an increased
formation in TLR4-cathepsin V complex
in response to HMGB1 that is inhibited
by SQV (Figure 3F). The expression levels
of TLR4, MyD88 and IRAK4 in the im-
munoprecipitations were similar and not
modified by SQV treatment (Figure 3E).
Recent studies have shown that HIV-
protease inhibitors can act as inhibitors
of the 20S core particle of the 26S protea-
some and the total 26S proteasome (24).
Thus, we also tested the effect of the
compounds on proteasome activity. We
found only weak inhibition of this target
by SQV in our screen (Supplementary
Table 2). Moreover, in our confirmatory
assay SQV and SID showed no inhibi-
tion, while 334 had only a weak effect at
higher concentration (Supplementary
Figure S4A). Proteasome inhibitors are
also potent blockers of the HMGB1-
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Figure 2. Identification of cathepsin V as a target for SQV and STO33438. (A) Effect of SQV
and 334 on cathepsin V activity. (B) Dose-dependent inhibition of recombinant cathepsin V
by SQV, 334, the cathepsin inhibitor, SID and the broad protease inhibitor E64. (C) Protein ex-
pression of cathepsin V and tubulin in human monocyte-derived macrophages transfected
with control or cathepsin V siRNA. (D) Human monocyte-derived macrophages were trans-
fected with control or cathepsin V siRNA and then assayed for HMGB1- dependent TNF-α
production by ELISA. (E) Dose-dependent effect of the cathepsin inhibitor SID on HMGB1-
 induced TNF-α release from human monocyte derived macrophages. (F) Cytotoxicity was
measured by LDH release into the cell media after 18 h of treatment.
 induced inflammatory cytokine produc-
tion, and complete inhibition of the pro-
teasome exerts similar protection to that
of SID, SQV and 334 (Supplementary
Figures S4B, C). Furthermore, both SID
and SQV act synergistically with the pro-
teasome inhibitor MG132 to block the
HMGB1-induced TNF-α production
(Supplementary Figures S4D, E) and thus
the antiinflammatory mode of action of
these compounds is independent of their
proteasome activity. In TLR4-driven cel-
lular responses, the 26S proteasome is re-
quired for signaling (for example, NF-κB
activation), which is downstream of the
signaling intermediates IRAK1. IRAK1 is
rapidly degraded after TLR stimulation
(25,26). To determine whether SQV acts
upstream of NF-κB, we assessed degra-
dation of IRAK1 in human monocyte-de-
rived macrophages exposed to HMGB1
for 30 and 60 min in presence or absence
of SQV. HMGB1 treatment led to the loss
of IRAK1, indicating its activation by
HMGB1 exposure as shown in the repre-
sentative Western blot (Figure 3G) with a
quantitation of multiple experiments pre-
sented in the histogram (Supplemental
Figure S3). These findings support the
conclusion that at least one of the targets
for the inhibitor is proximal to this sig-
naling intermediate.
SQV Protects in Models Known to be
Driven by the HMGB1-TLR4 Axis
Antibodies to HMGB1 are protective in
polymicrobial sepsis even as a posttreat-
ment strategy consistent with the known
role of HMGB1 as a late mediator of the
lethality in this condition (27). Here we
show that the administration of SQV or
334 given daily for 3 d starting at 24 h
after initiation of sepsis using a model
of cecal ligation and puncture (CLP) sig-
nificantly reduced mortality in mice (Fig-
ures 4A, B). Dosage was determined
based on dose-dependent toxicity shown
in Supplemental Figure S5. We have pre-
viously reported that early HMGB1-
 dependent TLR4 activation significantly
contributes to inflammation-associated
organ damage in the (I/R) model of ster-
ile inflammation (8). Pretreatment with
SQV (5 mg/kg bodyweight) (28) signifi-
cantly reduced liver damage in a murine
model of warm liver (I/R) involving 60
min of ischemia followed by 6 h of reper-
fusion, indicated by a significant reduc-
tion in ALT levels (Figure 4C). The dra-
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Figure 3. SQV inhibits the interaction between cathepsin V and the TLR4-Myddosome recep-
tor signaling complex. (A,B) HEK293 cells transfected with HA tagged TLR4 were immunopre-
cipitated for HA:TLR4 or cathepsin V followed by subsequent cathepsin V and or TLR4:HA im-
munobloting. (C) Recombinant human TLR4 and cathepsin V binding was measured by
surface plasmon resonance. SQV at 0.625, 1.25, 2.5, 5 μmol/L dose dependently inhibited
binding of TLR4 to cathepsin V. (D) Human monocyte-derived macrophages were pre-
treated with SQV (30 μmol/L for 1h) followed by the addition of HMGB1 for 30 and 60 min.
Representative immunoblot of immunoprecipitated cathepsin V or MYD88 blotted against
TLR4 and IRAK4. (E) Representative immunoblot of TLR4, IRAK4, cathepsin V and MYD88 total
protein expression used as input for the experiments in (D). (F) Histogram of quantitation of
multiple experiments from (D). (G) Effect of SQV on HMGB1-induced IRAK-1 protein expres-
sion compared with β-actin as determined by Western blot analysis.
matic inhibition of liver necrosis using
SQV was confirmed histologically and
the percent necrosis quantitated in each
image shows a strong reduction in necro-
sis in the liver of SQV-treated mice (Fig-
ure 4D). Therefore, SQV and 334 exert
potent protection in models of known
HMGB1-mediated immunopathology.
DISCUSSION
The interaction of the danger-associated
molecular pattern molecule (DAMP)
HMGB1 with pattern recognition recep-
tors, including TLR4, drives inflammation
in many acute and chronic conditions (1).
This led us to screen for inhibitors of the
TLR4-mediated pathway activated by
disulfide HMGB1. Using TNF-α produc-
tion by macrophages as a gold standard
to assess the response to disulfide
HMGB1, we identified first generation
HIV PIs from a screen of pharmacologi-
cally active and clinically used com-
pounds and subsequently identified
ST033438 (334) from a screen of known
protease inhibitors (18). Furthermore, we
discovered that cathepsin V is a unique
mammalian target for both SQV and 334.
Our studies also uncovered an unex-
pected role for cathepsin V in TLR4 sig-
naling, raising the possibility that cathep-
sin V inhibitors could be used to target
DAMP-induced inflammation.
SQV was introduced into clinical prac-
tice in 1995 as an inhibitor of the HIV
protease involved in viral replication
(29). However, SQV and other first gen-
eration HIV-PIs have been shown to re-
duce immunopathology and tissue dam-
age in several experimental models
including sepsis (30), pancreatitis (31)
and hypoxia-induced pulmonary arterial
hypertension (32). A recent clinical trial
showed that a 6-month course of SVQ
improves proteinurea in steroid-resistant
nephrotic syndrome (33). From these ex-
perimental and clinical studies it was
conceivable that a secondary, mam-
malian protease target exists for this class
of antiviral drugs. SQV has been shown
to suppress activity of the 20S core parti-
cle of the 26S proteasome as well as total
26S proteasome (25,26). By showing that
SQV blocks cathepsin V, we provide an-
other distinct mammalian target for first
generation HIV-PI. The importance of
cathepsin V as a target in the HMGB1-
TLR4 pathway is further supported by
our findings that SID26681509, a known
cathepsin inhibitor and 334, a novel pro-
tease inhibitor, block both disulfide
HMGB1-induced TNF-α production and
cathepsin V activity.
The role of cathepsins in disease and
as critical regulators of innate immunity
is slowly emerging (34). Cathepsins are a
family of multifunctional proteases that
include eleven cysteine cathepsins in hu-
mans. In general, cathepsins are synthe-
sized as proenzymes that are expressed
in lysosomes and are optimally activated
under acidic conditions to cleave a wide
array of protein targets (35). Cathepsins
B, K, L and S have been shown to be ex-
pressed mainly by macrophages. Func-
tions attributed to cysteine cathepsins
include cell death and inflammasome
signaling (36), antigen presentation (37),
collagen turnover in bone and cartilage
(38), vascular remodeling (39) and neu-
ropeptide and hormone processing (40).
Interestingly, endosomal TLRs, including
TLR3, 7 and 9 require cleavage that can
involve cathepsins B, K and H for ligand
recognition and activation (41–48). In the
setting of rheumatoid arthritis involving
TLR4 (49), psoriasis-like lesions involv-
ing TLR7 (50) and collagen-induced
arthritis involving TLR9 (51), cathepsins
have been shown to influence disease.
Less is known about the mammalian
cathepsin V, which is expressed in hu-
mans, pigs, cows, dogs and sheep but
not in mice, where cathepsin L repre-
sents the murine homologue (37,52).
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Figure 4. Inhibition of cathepsin is protective in in vivo models known to be driven via the
HMGB1-TLR4 axis (A,B) Survival curves of male BALB/c mice that underwent cecal ligation
and puncture (CLP). SQV or 334 was administered at 0.5 mg (SQV) or 5 mg (334) per mouse
(IP in 200 μL PBS-DMSO) per day for 3 d starting at 24 h after CLP surgery. Control mice in re-
ceived vehicle (PBS-DMSO) only. Animal survival was monitored for up to 2 wks. N = 20 mice
per group. *P < 0.05 versus control group. (C-D) C57BL6/J mice underwent 70% warm liver is-
chemia for 1 h followed by reperfusion for 6 h. Mice were treated with SQV or vehicle 1 h
prior to ischemia and again at the time of reperfusion. SQV attenuated liver I/R injury as
measured by (C) plasma ALT levels and (D) histological examination of H&E-stained liver
sections with indicated percent necrosis quantitated in each image.
While initial biodistribution studies only
demonstrated expression of cathepsin V
in testis, thymus and within the corneal
epithelium (53), it has since been de-
tected in skin (54), endothelial cells (55),
breast and colorectal carcinomas (56)
and human PBMCs (55). Polymorphisms
of cathepsin V have been associated
with diabetes and early onset myasthe-
nia gravis (57). Absence of cathepsin V
in mice (carrying the cathepsin L homo-
logue) limits our in vivo murine models
in establishing a direct link to cathepsin
V. We do show, however, that SQV pro-
tects the TLR4-HMGB1-induced pathol-
ogy. This is further confirmed using the
protease inhibitor compound 334. We
can thus not rule out other targets of
SQV, but are presenting solid data here
demonstrating that cathepsin V is one
target. Our present findings show that
cathepsin V is expressed in primary
human monocytes isolated from blood
(Supplementary Figure S6) and in a
human monocytic cell line where it
binds directly with TLR4. This interac-
tion, which is already present in unstim-
ulated cells, is intensified by HMGB1
treatment and blocked by SQV implicat-
ing cathepsin V in the formation of the
human TLR4 signaling complex. Sup-
port for a proximal target for SQV in
HMGB1-induced TLR4 signaling is pro-
vided by showing that SQV blocks the
interaction of MyD88 with the TLR4 sig-
naling complex and IRAK1 degradation;
steps involved in the formation and
function of the myddosome (58). These
results support the view that DAMP-
and pathogen-associated molecular pat-
tern molecule (PAMP)-mediated re-
sponses are already distinguished at the
receptor level even when the signals are
transmitted through the same toll-like
receptor.
CONCLUSION
In summary, the current studies iden-
tify cathepsin V as a novel target in
DAMP-driven inflammation and TLR4
signaling. The demonstration that an
FDA-approved drug with a well estab-
lished safety and toxicity profile func-
tions as a cathepsin V inhibitor may
open the door for therapeutic repurpos-
ing approaches for acute and chronic 
inflammation.
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